Inflammasome in Platelets: Allying Coagulation and Inflammation in Infectious and Sterile Diseases?

Eugenio D. Hottz, 1,2 Ana Paula T. Monteiro, 1 Fernando A. Bozza, 2,3 and Patrícia T. Bozza 1

1Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, 21040-900 Rio de Janeiro, RJ, Brazil
2Laboratório de Medicina Intensiva, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, 21040-900 Rio de Janeiro, RJ, Brazil
3Instituto D’Or de Pesquisa e Ensino, 22281-100 Rio de Janeiro, RJ, Brazil

Correspondence should be addressed to Fernando A. Bozza; bozza.fernando@gmail.com and Patrícia T. Bozza; pbozza@ioc.fiocruz.br

Received 19 September 2014; Revised 24 January 2015; Accepted 26 January 2015

Academic Editor: Bernardo S. Franklin

Copyright © 2015 Eugenio D. Hottz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Platelets are crucial effector cells in hemostasis. In addition, platelets are increasingly recognized as major inflammatory cells with key roles in innate and adaptive immune responses. Activated platelets have key thromboinflammatory activities linking coagulation to inflammatory response in a variety of coagulation disorders and vasculopathies. Recently identified inflammatory activities of platelets include the synthesis of IL-1β from spliced pre-RNA, as well as the presence and assembly of inflammasome which intermediate IL-1β secretion. Here we review the mechanisms by which platelets activate translation machinery and inflammasome assembly to synthesize and release IL-1β. The contributions of these processes to protective and pathogenic responses during infectious and inflammatory diseases are discussed.

1. Introduction

Platelets are classically known as essential and specialized effector cells in hemostasis. In large part due to their anucleate status, the activities attributed to platelets were for a long time restricted to their procoagulant and wound healing functions, with rapid responses involving aggregation and granule secretion. Nevertheless, recent studies have shown a new repertoire of platelet activities mainly related to immune and inflammatory responses [1, 2]. Even though platelets do not have nuclei, they have stored RNA molecules and diverse mechanisms for posttranscriptional process RNA using specialized pathways to change their proteome, phenotype, and functions [3]. In addition, platelets are relatively long-living cells and can mediate responses for many hours after initial adhesion, aggregation, and secretion. Consonant with the recent advance in platelet biology, newly recognized inflammatory activities continue to emerge in platelets. An important find in this field was the recent demonstration of platelets assembling of functional inflammasome to process and secrete biologically active interleukin-1β (IL-1β) [4].

IL-1β is the best described newly synthesized protein after pro–RNA splicing in platelets [3, 5, 6]. This cytokine is linked to endothelial dysfunction and coagulation disorders in many inflammatory, infectious, and cardiovascular diseases [7–10]. It activates cells of the immune system and of the vascular wall through IL-1 receptor (IL-1R) signaling promoting inflammation, angiogenesis, and differentiation of myeloid progenitor cells [11]. IL-1β activity in activated platelets has been extensively reported in the last two decades [5, 6, 12–15], including the pathways involved in IL-1β synthesis [3, 5, 6]. However, the pathways involved in processing and secretion of IL-1β by platelets, including requirement of inflammasome, were only recently dissected [4, 6, 16]. Here we provide an overview of platelet inflammatory responses that require IL-1β signaling and inflammasome activation. We emphasize the potential
implication of these pathways to inflammatory activities of platelets in diverse vasculopathies and coagulopathies in response to pathogens or sterile stimuli.

2. Inflammasome Signaling in Platelets

Inflammasome activation in nucleated cells usually needs two distinct signal cascades from pattern recognition receptors (PRR). The first one, also termed priming, culminates in translocation of NFκB to the nucleus and synthesis of IL-1β, IL-18, and the inflammasome components. The second signal follows the activation of a cytosolic recognition system of pathogen-associated or damage-associated molecular patterns (PAMP and DAMP, resp.). The better characterized inflammasome uses NOD-like receptor containing domain pyrin 3 (NLRP-3) as sensor, which recruits the adaptor apoptosis-associated speck-like protein containing a CARD domain (ASC) and the proteolytic subunit caspase-1 to assemble the inflammasome and process IL-1β and/or IL-18 into mature cytokines [17–19]. We recently described that platelets constitutively express the inflammasome components NLRP3 and ASC and can use them to assemble functional inflammasome, activate caspase-1, and process IL-1β [4]. In addition to constitutively expressed proteins, inflammasome components are also detected at the transcriptional level in platelets [20]. The signaling pathways for IL-1β synthesis and inflammasome activation demonstrated in platelets up to the moment are highlighted here and summarized in Figure 1.

As aforementioned, platelets have stored RNA molecules; many of them present as pre-RNA and need spliceosome-dependent mechanisms for their processing into mature transcripts [3, 21]. Signal-dependent splicing of IL-1β pre-mRNA in activated platelets is controlled by cdc-like Kinase 1 (CLK1) [6, 22]. This mechanism is activated by thrombin or other classic agonists in the presence of fibrinogen and requires outside-in signaling from integrin αIIbβ3 engagement to fibrin during clot formation [3, 5, 21]. CLK-1-mediated IL-1β RNA splicing also occurs after Toll-like receptor- (TLR-) 2- and TLR-4-mediated platelet activation by Pam3Cys or LPS, respectively [6, 16, 22]. As in nucleated cells, LPS engagement to TLR-4 on platelets leads to recruitment of MyD88 adaptor and phosphorylation of IRAK1 and 4 [6]. TRAF6 couples MyD88 signaling to AKT/JNK pathway, leading to IL-1β RNA splicing in LPS-stimulated platelets [6]. As platelets themselves do not express CD14 [23], LPS-induced IL-1β RNA processing is potentiated in the presence of sCD14 [22]. Surprisingly, anucleate platelets have transcription factors as NFκB and STAT3, which present nontranscriptional activities in these cells [24, 25]. LPS or Pam3Cys activation of TLR-4 or -2 on platelets results in IkB degradation and NFκB-dependent platelet responses [24]. However, the requirement of NFκB for IL-1β synthesis in platelets remains to be determined.

Platelets express the lectin receptor dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) which recognizes pathogen-associated carbohydrates [26, 27]. DC-SIGN also recognizes glycosylated domains on the envelope protein of dengue virus (DENV) [28, 29], and DENV activates
platelets depending on DC-SIGN expression [30]. We have recently demonstrated that platelet activation by DENV induces IL-1β synthesis and secretion [4]. In this study [4] we showed through flow cytometry and confocal fluorescence microscopy that freshly isolated platelets constitutively express the inflammasome components NLRP3 and ASC, which were dissociated in rested platelets but colocalized in activated platelets from patients with dengue, indicating presence of assembled inflammasomes during dengue disease. This was consistent with increased caspase-1 activity in platelets from patients or platelets stimulated with DENV in vitro and the ability of YVAD-fmk caspase-1 inhibitor to impair IL-1β secretion by DENV-activated platelets. Finally, cleaved IL-1β was detected in platelets from DENV-infected patients using western blot analysis [4]. These observations of platelets from patients with dengue, as well as from in vitro infection models and functional assays, provided the first evidence for inflammasome activity in platelets, and its assembly during DENV infection culminating in the release of IL-1β.

Inflammasome activation in DENV-stimulated platelets required as second signaling the generation of reactive oxygen species (ROS) in mitochondria [4], consistent with ROS-mediated NLRP3 inflammasome activation in monocytes [19, 31]. Curiously, caspase-1-dependent IL-1β processing in thrombin- or LPS-stimulated platelets do not require the addition of a second stimulus [5, 6, 16, 22] as required by LPS-primed nucleated cells [17–19]. Platelet activation induces secretion of ATP from dense granules [24, 32, 33] and NLRP3-inflammasome responds to extracellular ATP [34]. Mitochondria-derived ROS and/or ATP from dense granule are likely involved in inflammasome activation after procoagulant or TLR stimulation.

Platelet-produced IL-1β is chiefly secreted in microparticles (MP), as after thrombin stimulation [5], as in PRR activation by LPS or DENV [4, 6, 16]. Interestingly, shedding of IL-1β-containing MPs is damped by caspase-1 inhibitors [4, 16], demonstrating that IL-1β packaging and secretion in MPs are uncoupled from IL-1β synthesis and depend on active inflammasomes. This notion was reinforced by Brown and McIntire [6], who showed that TRAF6 activation induces AKT/JNK phosphorylation and IL-1β synthesis without inducing the shedding of MPs.

Platelets and megakaryocytes express IL-1R on surface and respond to IL-1β [16, 35]. IL-1β stimulates megakaryocyte maturation and enhances platelet aggregation and adhesion in response to collagen and fibrinogen [35]. The signaling cascade after IL-1β-IL-1R engagement is very similar to TLR agonist stimulation [6, 24, 35]. Thus, IL-1β signals its own synthesis in platelets and an IL-1β autocrine loop potentiate IL-1β synthesis and shedding of IL-1β-rich MPs in LPS-activated platelets [16].

3. Platelet Inflammasome in Sterile Thrombosis and Inflammation

Platelets become activated by contact with matrix proteins and/or von Willebrand factor exposed on endothelial cells after interaction with injured endothelium [36–38]. This initial procoagulant response is amplified by platelet-secreted agonists and by adhesion of integrin α5β3 to fibrin mesh [37, 39]. During this process, platelets synthesize, process, and secrete IL-1β in response to different procoagulant stimuli including endothelial matrix proteins (collagen) and secreted agonists (thrombin, ADP, epinephrine and PAF) [5]. Part of the IL-1β synthesized in platelets remains as cell-associated cytokine [5]. Activated platelets interact with and signal inflammatory responses to endothelial cells; many of these responses involve IL-1β signaling [13, 14, 38]. Importantly, in vitro models for clot formation and retraction show IL-1β accumulation in platelet-fibrin clump [5] and IL-1β is found in occlusive thrombus in vivo few hours after damage of vascular wall induced by FeCl3 [16]. IL-1β accumulation in arterial thrombosis in vivo precedes mononuclear leukocytes incorporation to the clot and is not affected by transcription inhibition, which damps IL-1β synthesis in leukocytes but not in platelets [16]. Thus, platelet-generated IL-1β accumulates in sterile thrombi allowing coagulation to local inflammation of the endothelium. However, whether and how inflammasomes are activated in platelets under sterile thrombosis deserve further investigation.

When endothelial cells are exposed to activated platelets or conditioned medium from activated platelets they release cytokines and chemokines including IL-6, IL-8, MCP-1, and GM-CSF [13, 14, 40]. This signaling is blocked by IL-1R antagonist [13, 14]. Moreover, during vascular injury platelets and platelet products gain access to the extravascular milieu, and vascular smooth muscle cells secrete proinflammatory cytokines in response to IL-1β from platelets [12]. Endothelial cells exposed to IL-1β-expressing platelets or platelet-derived MPs express the adhesion molecules ICAM-1 and VCAM-1 depending on IL-1R [6, 14] and support the adhesion of polymorphonuclear (PMN) neutrophils [5]. IL-1R-mediated neutrophils transendothelial migration takes place after activation of brain microvascular EC monolayers with supernatant from activated platelets, and neutrophils infiltration to brain tissue occurs after cerebral ischemia in vivo close to ICAM-1-expressing vessels with adherent platelets [41].

Infiltration of neutrophils and platelet-derived MPs are also observed in the synovial fluid from patients with rheumatoid arthritis [42]. Analyses of experimental rheumatoid arthritis together with in vitro models for platelet-synoviocyte interaction indicate that platelets become activated in the inflamed joint by local exposure to collagen or collagen-producing fibroblast-like synoviocytes (FLS). These platelets shed IL-1α- and IL-1β-containing MPs which reciprocally activate resident fibroblast-like synoviocytes in the synovial space. MPs-activated synoviocytes secrete proinflammatory cytokines and chemokines including IL-6, IL-8, and MCP-1, amplifying inflammation in synovial compartment [42].

4. Platelet Inflammasome in Infectious Diseases

Infectious disease continues to be a leading cause of death globally. Platelet activation, including shedding of MPs, plays
pathogenic roles in several clinical conditions such as dengue, sepsis, malaria, and HIV/AIDS syndromes [4, 30, 43–46].

Among many ways in which platelets can intermediate inflammatory and immune responses in infectious diseases [1, 2] recent evidence highlights the roles for inflammasome in platelets [4] and the relevance of platelets as main sources of IL-1β [47]. Contributions of platelet IL-1β synthesis and inflammasome activation to infectious diseases models are summarized here.

It has been demonstrated elsewhere [22] that LPS (even at low concentrations) can start IL-1β RNA processing in platelets, with translation and accumulation of IL-1β protein. Comparing the synthesis and accumulation of IL-1β, LPS exhibits a more robust response than classical platelet agonists as thrombin and collagen [5]. Because gram negative bacterial sepsis is a major clinical problem with few therapeutic options, much interest has been on the implications for LPS activation of platelet TLR4 to the pathogenesis of inflammatory and immune responses in infectious diseases.
of sepsis and endotoxemia [6, 16, 48]. Shedding of IL-1β-containing MPs is a major response to LPS in platelets [6, 16]. IL-1β-containing MPs recovered from LPS-stimulated platelets activate IL-1R on endothelial cells leading to VCAM-1 expression [6]. Endothelial activation with compromising of cardiovascular system is a leading cause of shock during severe sepsis. Inflammation participates in this process and is associated with local thrombosis. Considering the endothelial role in cardiovascular aspect of sepsis, MPs-induced activation of endothelium uncovers a potential role for platelet IL-1β in septic syndrome.

During experimental cerebral malaria in mice, activated platelets are the main source of circulating IL-1β [47]. Malaria is a tropical infectious disease caused by mosquito-borne Plasmodium parasites. Inflammatory vasculopathy is a feature of severe malaria, which includes cerebral malaria and pulmonary malaria. Sequestration of platelets with leukocytes and parasitized red blood cells in the vascular bed with activation of the coagulation cascade and disruption of endothelial barrier function are thought to contribute to vasculopathy in severe malaria [49, 50]. Platelet activation and thrombocytopenia occur early in complicated malaria [47, 51]. In murine model for cerebral malaria, early platelet activation is protective by inducing the acute phase response and limiting parasite burden [47], while continued platelet activation is detrimental to the host probably by contributing to vasculopathy [52]. Platelet-induction of acute phase response at the liver depends on IL-1β synthesis and secretion by platelets [47], highlighting the potential role for platelet inflammasome in protective responses during severe malaria.

Dengue is an arthropod-born viral disease caused by the four dengue virus serotypes (DENV 1–4). DENV infection induces a spectrum of clinical manifestations that range from mild self-limited dengue fever to severe dengue, a life-threatening syndrome associated with increased vascular permeability, hypovolemia, hypotension, and shock [53, 54]. Thrombocytopenia is commonly observed in dengue syndromes and correlates with the onset of plasma leakage and with risk for severe dengue [7, 54–57]. IL-1β is an important proinflammatory cytokine increased during severe dengue [7, 8, 58]. Of note, increased IL-1β levels associate with thrombocytopenia, increased endothelial permeability [7], thrombosis, and dysregulated hemostasis in dengue disease [8]. We recently reported increased expression of IL-1β in platelets from patients with dengue and in platelets exposed to DENV in vitro. We demonstrated that dengue induces NLRP3-inflammasome assembly and caspase-1-dependent IL-1β secretion in platelets. IL-1β was also detected in platelet MPs from patients with dengue and in MPs from platelets activated by DENV in vitro. Importantl, platelet synthesis of IL-1β, inflammasome activation, and shedding of IL-1β-containing MPs were correlated with clinical signs of increased vascular permeability in dengue patients, and MPs recovered from DENV-activated platelets increased endothelial cell permeability in vitro depending on IL-1R [4]. This translational study demonstrates that DENV-triggered IL-1β synthesis in platelets is a mechanism for endothelial activation and increased vascular permeability in dengue syndrome.

5. Conclusion

Inflammasome components and mechanisms for inflammasome activation were only recently described in platelets, which opens new perspectives and research opportunities in diseases pathogenesis. As discussed above, IL-1β synthesis and inflammasome processing of IL-1β in platelets are implicated in a range of inflammatory and infectious conditions. The immune and inflammatory activities of platelets that require inflammasome activation and IL-1β signaling are summarized in Figure 2. This review highlighted our basic knowledge on platelet inflammasome and the signaling cascades needed to its activation. Currently, there is little information regarding inflammasome in platelets. While NLRP3 inflammasome was recently demonstrated in platelets [4], a range of inflammasomes that respond to different inflammatory stimulus and pathogens remain to be described in these important effector cells. Synthesis of IL-1β by platelets and IL-1β shedding in platelet MPs have been implicated in diverse pathologies including inflammatory, thromboembolic, and infectious diseases [4, 16, 42, 47]. However, conditions in which platelet inflammasomes play pathogenic and/or protective roles still deserve more in-depth investigation. Commitment to this investigative front will undoubtedly identify new hemostatic and inflammatory roles for platelet IL-1β and inflammasome.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this article.

References

[1] J. W. Semple, J. E. Italiano Jr., and J. Freedman, “Platelets and the immune continuum,” Nature Reviews Immunology, vol. 11, no. 4, pp. 264–274, 2011.
[2] A. Vieira-de-Abreu, R. A. Campbell, A. S. Weyrich, and G. A. Zimmerman, “Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum,” Seminars in Immunopathology, vol. 34, no. 1, pp. 5–30, 2012.
[3] M. M. Denis, N. D. Tolley, M. Bunting et al., “Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets,” Cell, vol. 122, no. 3, pp. 379–391, 2005.
[4] E. D. Hottz, J. F. Lopes, C. Freitas et al., “Platelets mediate increased endothelial permeability in dengue through NLRP3-inflammasome activation,” Blood, vol. 122, no. 20, pp. 3405–3414, 2013.
[5] S. Lindemann, N. D. Tolley, D. A. Dixon et al., “Activated platelets mediate inflammatory signaling by regulated interleukin Ibeta synthesis,” The Journal of Cell Biology, vol. 154, no. 3, pp. 485–490, 2001.
[6] G. T. Brown and T. M. McIntyre, “Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1β-rich microparticles,” Journal of Immunology, vol. 186, no. 9, pp. 5489–5496, 2011.
[7] F. A. Bozza, O. G. Cruz, S. M. O. Zagne et al., “Multiplex cytokine profile from dengue patients: MIP-Ibeta and IFN-gamma as predictive factors for severity,” BMC Infectious Diseases, vol. 8, article 86, 2008.
C. Suharti, E. C. M. van Gorp, T. E. Setiati et al., “The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome,” *Thrombosis and Haemostasis*, vol. 87, no. 1, pp. 42–46, 2002.

D. P. Abulafia, J. P. de Rivera Vaccari, J. D. Lozano, G. Lotocki, R. W. Keane, and W. D. Dietrich, “Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 29, no. 3, pp. 534–544, 2009.

H. Yang, H.-J. Ko, J.-Y. Yang et al., “Interleukin-1 promotes coagulation, which is necessary for protective immunity in the lung against streptococcus pneumoniae infection,” *Journal of Infectious Diseases*, vol. 207, no. 1, pp. 50–60, 2013.

C. A. Dinarello, “Immunological and inflammatory functions of the interleukin-1 family,” *Annual Review of Immunology*, vol. 27, pp. 519–559, 2009.

H. Loppnow, R. Bil, S. Hirt et al., “Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells,” *Blood*, vol. 91, no. 1, pp. 134–141, 1998.

G. Kaplanski, R. Porat, K. Aiura, J. K. Erban, J. A. Gelfand, and C. A. Dinarello, “Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event,” *Blood*, vol. 81, no. 10, pp. 2492–2495, 1993.

C. M. Hawrylowicz, G. L. Howells, and M. Feldmann, “Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production,” *Journal of Experimental Medicine*, vol. 174, no. 4, pp. 785–790, 1991.

C. M. Hawrylowicz, S. A. Santoro, F. M. Platt, and E. R. Unanue, “Activated platelets express IL-1 activity,” *Journal of Immunology*, vol. 143, no. 12, pp. 4015–4018, 1989.

G. T. Brown, P. Narayanan, W. Li, R. L. Silverstein, and T. M. McIntyre, “Lipopolysaccharide stimulates platelets through an IL-beta autocrine loop,” *Journal of Immunology*, vol. 191, no. 10, pp. 5196–5203, 2013.

B. K. Davis, H. Wen, and J. P.-Y. Ting, “The Inflammasome NLRs in immunity, inflammation, and associated diseases,” *Annual Review of Immunology*, vol. 29, pp. 707–735, 2011.

M. Lampkanf and V. M. Dixo, “Modulation of inflammasome pathways by bacterial and viral pathogens,” *The Journal of Immunology*, vol. 187, no. 2, pp. 597–602, 2011.

R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, “A role for mitochondria in NLRP3 inflammasome activation,” *Nature*, vol. 469, no. 7329, pp. 221–226, 2011.

J. W. Rowley, A. J. Oler, N. D. Tolley et al., “Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes,” *Blood*, vol. 118, no. 14, pp. e101–e111, 2011.

H. Schwartz, N. D. Tolley, J. M. Foulks et al., “Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets,” *Journal of Experimental Medicine*, vol. 203, no. 11, pp. 2433–2440, 2006.

P. N. Shashkin, G. T. Brown, A. Ghosh, G. K. Marathe, and T. M. McIntyre, “Lipopolysaccharide is a direct agonist for platelet RNA splicing,” *Journal of Immunology*, vol. 181, no. 5, pp. 3495–3502, 2008.

A.-L. Ståhl, M. Svensson, M. Mörgelin et al., “Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome,” *Blood*, vol. 108, no. 1, pp. 167–176, 2006.

L. Rivadeneyra, A. Carestia, J. Etulain et al., “Regulation of platelet responses triggered by Toll-like receptor 2 and 4 ligands is another non-genomic role of nuclear factor-kappaB,” *Thrombosis Research*, vol. 133, no. 2, pp. 235–243, 2014.

Z. Zhou, F. C. Gushiken, D. Bolgiano et al., “Signal transducer and activator of transcription 3 (STAT3) regulates collagen-induced Platelet aggregation independently of its transcription factor activity,” *Circulation*, vol. 127, no. 4, pp. 476–485, 2013.

S. Boukour, J.-M. Massé, L. Bénit, A. Dubart-Kuppenschmitt, and E. M. Cramer, “Lentivirus degradation and DC-SIGN expression by human platelets and megakaryocytes,” *Journal of Thrombosis and Haemostasis*, vol. 4, no. 2, pp. 426–435, 2006.

C. Flaujac, S. Boukour, and E. Cramer-Bordé, “Platelets and viruses: an ambivalent relationship,” *Cellular and Molecular Life Sciences*, vol. 67, no. 4, pp. 545–556, 2010.

E. Pokidysheva, Y. Zhang, A. J. Battisti et al., “Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN,” *Cell*, vol. 124, no. 3, pp. 485–493, 2006.

B. Tassaneentrithep, T. H. Burgess, A. Granelli-Piperno et al., “DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells,” *Journal of Experimental Medicine*, vol. 197, no. 7, pp. 823–829, 2003.

E. D. Hottz, M. F. Oliveiera, P. C. G. Nunes et al., “Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases,” *Journal of Thrombosis and Haemostasis*, vol. 11, no. 5, pp. 951–962, 2013.

J. E. Vincé, W. W.-L. Wong, J. Gentle et al., “Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation,” *Immunity*, vol. 36, no. 2, pp. 215–227, 2012.

P. P. Lemons, D. Chen, A. M. Bernstein, M. K. Bennett, and S. W. Whiteheart, “Regulated secretion in platelets: identification of elements of the platelet exocytosis machinery,” *Blood*, vol. 90, no. 4, pp. 1490–1500, 1997.

F. Rendu and B. Brohard-Bohn, “The platelet release reaction: granules’ constituents, secretion and functions,” *Platelets*, vol. 12, no. 5, pp. 261–273, 2001.

F. Martinon, V. Petrelli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” *Nature*, vol. 440, no. 7081, pp. 237–241, 2006.

L. M. Beaulieu, E. Lin, E. Mick et al., “Interleukin 1 receptor 1 and interleukin 1β regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans,” *Artherosclerosis, Thrombosis, and Vascular Biology*, vol. 34, no. 3, pp. 552–564, 2014.

D. Varga-Szabo, I. Pleines, and B. Nieswandt, “Cell adhesion mechanisms in platelets,” *Artherosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 3, pp. 403–412, 2008.

J. E. Freedman, “Molecular regulation of platelet-dependent thrombosis,” *Circulation*, vol. 112, no. 17, pp. 2725–2734, 2005.

S. Nishimura, I. Manabe, M. Nagasaki et al., “In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling,” *Blood*, vol. 119, no. 8, pp. e45–e56, 2012.

S. J. Shattil, C. Kim, and M. H. Ginsberg, “The final steps of integrin activation: the end game,” *Nature Reviews Molecular Cell Biology*, vol. 11, no. 4, pp. 288–300, 2010.

M. Gawaz, F.-J. Neumann, T. Dickfeld et al., “Activated platelets induce monocyte chemotactic protein-1 secretion and surface
Mediators of Inflammation express of intercellular adhesion molecule-1 on endothelial cells, "Circulation, vol. 98, no. 12, pp. 1164–1171, 1998.

[41] P. Thornton, B. W. McColl, A. Greenhalgh, A. Denes, S. M. Allan, and N. J. Rothwell, "Platelet interleukin-1 alpha drives cerebrovascular inflammation," "Blood, vol. 115, no. 17, pp. 3632–3639, 2010.

[42] E. Boilard, P. A. Nigrovic, K. Larabee et al., "Platelet interleukin-1 alpha drives cerebrovascular inflammation," "Blood, vol. 115, no. 17, pp. 3632–3639, 2010.

[43] E. D. Hottz, I. M. Medeiros-de-Moraes, A. Vieira-de-Abreu et al., "Platelet activation and apoptosis modulate monocyte inflammatory responses in dengue," "The Journal of Immunology, vol. 193, no. 4, pp. 1864–1872, 2014.

[44] M. T. Rondina, H. Schwetz, E. S. Harris et al., "The septic milieu triggers expression of spliced tissue factor mRNA in human platelets," "Journal of Thrombosis and Haemostasis, vol. 9, no. 4, pp. 748–758, 2011.

[45] F. M. Campos, B. S. Franklin, A. Teixeira-Carvalho et al., "Augmented plasma microparticles during acute Plasmodium vivax infection," "Malaria Journal, vol. 9, no. 1, article 327, 2010.

[46] G. Andonegui, S. M. Kerfoot, K. McNagny, K. V. J. Ebbert, K. D. Patel, and P. Kubes, "Platelets express functional Toll-like receptor-4," "Blood, vol. 106, no. 7, pp. 2417–2423, 2005.

[47] C. A. Moxon, S. C. Wassmer, D. A. Millner Jr. et al., "Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children," "Blood, vol. 122, no. 5, pp. 842–851, 2013.

[48] K. I. Schexneider and E. A. Reedy, "Thrombocytopenia in dengue fever," "Current hematology reports, vol. 4, no. 2, pp. 179–187, 2008.

[49] S. Bhatt, P. W. Gething, O. J. Brady et al., "The global distribution and burden of dengue," "Nature, vol. 496, no. 7446, pp. 504–507, 2013.

[50] WHO, "Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control, 2009.

[51] K. I. Schexneider and E. A. Reedy, "Thrombocytopenia in dengue fever," "Current hematology reports, vol. 4, no. 2, pp. 145–148, 2005.

[52] M. P. G. Mourão, M. V. G. Lacerda, V. O. Macedo, and J. B. Santos, "Thrombocytopenia in patients with dengue virus infection in the Brazilian Amazon," "Platelets, vol. 18, no. 8, pp. 605–612, 2007.

[53] E. Hottz, N. D. Tolley, G. A. Zimmerman, A. S. Weyrich, and F. A. Bozza, "Platelets in dengue infection," "Drug Discovery Today: Disease Mechanisms, vol. 8, no. 1-2, pp. e33–e38, 2011."